FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281714164> ?p ?o ?g. }

• W4281714164 endingPage "974" @default.
• W4281714164 startingPage "965" @default.
• W4281714164 abstract "Inflammation plays an important role in the initiation and progression of atherosclerosis, leading to poor clinical outcomes. Hyperuricemia is associated with the activation of the Nod-like receptor protein 3 inflammasome. Here, we investigated whether inhibition of inflammation using febuxostat lowered the risk of cardiovascular events.This is a post-hoc analysis of the randomized trial, Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy (FREED). In total, 1067 patients (736 men and 331 women) were included in the analysis. We compared the serial changes in high-sensitivity C-reactive protein (hs-CRP) levels between febuxostat and non-febuxostat groups and assessed the correlation between the changes in uric acid (UA) and hs-CRP levels after febuxostat treatment. We also determined whether febuxostat could reduce a hard endpoint, defined as a composite of cardiovascular events and all-cause mortality.Serum UA levels in the febuxostat group were significantly lower than those in the non-febuxostat group after randomization (p < 0.05). However, hs-CRP levels were comparable between the two groups during the study. No significant correlation was observed between the changes in UA and hs-CRP levels after febuxostat treatment. The hard endpoints did not differ significantly between the two groups. In patients with baseline hs-CRP levels > 0.2 mg/dL or those administered 40 mg of febuxostat, the drug did not reduce hs-CRP levels or decrease the hard endpoint.Febuxostat reduced the UA levels but did not affect the CRP levels, and therefore may fail to improve cardiovascular outcomes after treatment.ClinicalTrial.gov (NCT01984749). https://clinicaltrials.gov/ct2/show/NCT01984749." @default.
• W4281714164 created "2022-06-13" @default.
• W4281714164 creator A5009760063 @default.
• W4281714164 creator A5011399496 @default.
• W4281714164 creator A5020090012 @default.
• W4281714164 creator A5020527263 @default.
• W4281714164 creator A5023570449 @default.
• W4281714164 creator A5023792530 @default.
• W4281714164 creator A5037592709 @default.
• W4281714164 creator A5040477783 @default.
• W4281714164 creator A5043809808 @default.
• W4281714164 creator A5047881217 @default.
• W4281714164 creator A5048525796 @default.
• W4281714164 creator A5050243057 @default.
• W4281714164 creator A5054229279 @default.
• W4281714164 creator A5054257222 @default.
• W4281714164 creator A5054780917 @default.
• W4281714164 creator A5066956159 @default.
• W4281714164 creator A5070648501 @default.
• W4281714164 creator A5073078229 @default.
• W4281714164 creator A5085420639 @default.
• W4281714164 creator A5090938829 @default.
• W4281714164 date "2022-06-01" @default.
• W4281714164 modified "2023-10-17" @default.
• W4281714164 title "C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study" @default.
• W4281714164 cites W1985749449 @default.
• W4281714164 cites W2012191117 @default.
• W4281714164 cites W2049267620 @default.
• W4281714164 cites W2051278307 @default.
• W4281714164 cites W2091800974 @default.
• W4281714164 cites W2107419879 @default.
• W4281714164 cites W2141653683 @default.
• W4281714164 cites W2149960660 @default.
• W4281714164 cites W2151834039 @default.
• W4281714164 cites W2296976312 @default.
• W4281714164 cites W2335302945 @default.
• W4281714164 cites W2525149912 @default.
• W4281714164 cites W2576559149 @default.
• W4281714164 cites W2748400555 @default.
• W4281714164 cites W2789006309 @default.
• W4281714164 cites W2889116610 @default.
• W4281714164 cites W2920558304 @default.
• W4281714164 cites W2922206684 @default.
• W4281714164 cites W2954782052 @default.
• W4281714164 cites W2986700515 @default.
• W4281714164 cites W2991474688 @default.
• W4281714164 cites W2996250016 @default.
• W4281714164 cites W3016659031 @default.
• W4281714164 cites W3023256684 @default.
• W4281714164 cites W3083862515 @default.
• W4281714164 cites W3092323790 @default.
• W4281714164 cites W4385826776 @default.
• W4281714164 cites W3174461150 @default.
• W4281714164 doi "https://doi.org/10.1007/s10557-022-07347-7" @default.
• W4281714164 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35648242" @default.
• W4281714164 hasPublicationYear "2022" @default.
• W4281714164 type Work @default.
• W4281714164 citedByCount "1" @default.
• W4281714164 countsByYear W42817141642022 @default.
• W4281714164 crossrefType "journal-article" @default.
• W4281714164 hasAuthorship W4281714164A5009760063 @default.
• W4281714164 hasAuthorship W4281714164A5011399496 @default.
• W4281714164 hasAuthorship W4281714164A5020090012 @default.
• W4281714164 hasAuthorship W4281714164A5020527263 @default.
• W4281714164 hasAuthorship W4281714164A5023570449 @default.
• W4281714164 hasAuthorship W4281714164A5023792530 @default.
• W4281714164 hasAuthorship W4281714164A5037592709 @default.
• W4281714164 hasAuthorship W4281714164A5040477783 @default.
• W4281714164 hasAuthorship W4281714164A5043809808 @default.
• W4281714164 hasAuthorship W4281714164A5047881217 @default.
• W4281714164 hasAuthorship W4281714164A5048525796 @default.
• W4281714164 hasAuthorship W4281714164A5050243057 @default.
• W4281714164 hasAuthorship W4281714164A5054229279 @default.
• W4281714164 hasAuthorship W4281714164A5054257222 @default.
• W4281714164 hasAuthorship W4281714164A5054780917 @default.
• W4281714164 hasAuthorship W4281714164A5066956159 @default.
• W4281714164 hasAuthorship W4281714164A5070648501 @default.
• W4281714164 hasAuthorship W4281714164A5073078229 @default.
• W4281714164 hasAuthorship W4281714164A5085420639 @default.
• W4281714164 hasAuthorship W4281714164A5090938829 @default.
• W4281714164 hasBestOaLocation W42817141642 @default.
• W4281714164 hasConcept C126322002 @default.
• W4281714164 hasConcept C134018914 @default.
• W4281714164 hasConcept C168563851 @default.
• W4281714164 hasConcept C203092338 @default.
• W4281714164 hasConcept C2776914184 @default.
• W4281714164 hasConcept C2779721657 @default.
• W4281714164 hasConcept C2779881121 @default.
• W4281714164 hasConcept C2780932893 @default.
• W4281714164 hasConcept C2781195455 @default.
• W4281714164 hasConcept C67761136 @default.
• W4281714164 hasConcept C71924100 @default.
• W4281714164 hasConcept C90924648 @default.
• W4281714164 hasConcept C98274493 @default.
• W4281714164 hasConceptScore W4281714164C126322002 @default.
• W4281714164 hasConceptScore W4281714164C134018914 @default.
• W4281714164 hasConceptScore W4281714164C168563851 @default.
• W4281714164 hasConceptScore W4281714164C203092338 @default.

• next